

# 2018 Statement of Financial Position

Phoenix Bioinformatics Corporation  
As of December 31, 2018

Prepared by Connie NG

# 2018 Statement of Financial Position

## Phoenix Bioinformatics Corporation As of December 31, 2018

DEC 31, 2018

### Assets

#### Current Assets

##### Cash and Cash Equivalents

BioCyc Account Citibank	165,686
Incoming Funds Citibank	139,170
Operations Citibank	353,489
Schwab Cash Account	712
Schwab Investment Account	733,053
AgBase Account Citibank	8,448
<b>Total Cash and Cash Equivalents</b>	<b>1,400,558</b>

Accounts Receivable	184,972
Prepaid Expenses	3,891
<b>Total Current Assets</b>	<b>1,589,421</b>

#### Fixed Assets

Database and Software	846,954
Accum Depr - Database and Software	(622,791)
Computer Equipment	12,034
Accum Depr - Computer Equipment	(4,007)
Leasehold Improvements	14,846
Accum Depr - Leasehold Imps	(6,186)
Construction In Progress	170,812
<b>Total Fixed Assets</b>	<b>411,662</b>

#### Long Term Assets

Security Deposits Asset	5,576
<b>Total Long Term Assets</b>	<b>5,576</b>

<b>Total Assets</b>	<b>2,006,659</b>
---------------------	------------------

### Liabilities and Net Assets

#### Liabilities

##### Current Liabilities

Accounts Payable	94,572
Accrued Employee Benefit Expenses	75
Accrued Expense CalChoice	232
Accrued Leave	53,460
Accrued Earned BioCyc Revenue Payable to SRI	50,445
BioCyc Unearned Revenue	210,555
Deferred Grant Revenue	127,687
Unearned or Deferred Revenue	699,418
Capital One Credit Card	7,077
<b>Total Current Liabilities</b>	<b>1,243,522</b>

DEC 31, 2018

<b>Long Term Liabilities</b>	
Tenant Improvement Financing	5,761
<b>Total Long Term Liabilities</b>	<b>5,761</b>
<b>Total Liabilities</b>	<b>1,249,283</b>
<b>Net Assets</b>	
<b>Unrestricted</b>	
Undesignated	603,688
Operating Reserve Fund	26,000
<b>Total Unrestricted</b>	<b>629,688</b>
Temporarily Restricted	127,687
<b>Total Net Assets</b>	<b>757,376</b>
<b>Total Liabilities and Net Assets</b>	<b>2,006,659</b>

# 2018 Statement of Activities

## Phoenix Bioinformatics Corporation For the year ended December 31, 2018

	UNRESTRICTED	TEMPORARILY RESTRICTED	TOTAL
<b>Income</b>			
Program Service Fees	20,510	-	20,510
Consulting Services	8,044	-	8,044
Foundation and Trust Grants	224,629	77,550	302,179
Individ, Business Contributions	522	-	522
BioCyc Subscription Revenue	38,209	-	38,209
<b>Program Subscriptions - TAIR</b>			
Subscription - Country and Consortiums	329,311	-	329,311
Corporate	136,979	-	136,979
Nonprofit and Academic	612,015	-	612,015
Individual and Lab	38,362	-	38,362
<b>Total Program Subscriptions - TAIR</b>	<b>1,116,666</b>	<b>-</b>	<b>1,116,666</b>
Wire Transfer Service Charge	3,155	-	3,155
Net Assets Released from Restriction	349,863	(349,863)	-
AgBase Subscription Revenue	69	-	69
<b>Total Income</b>	<b>1,761,667</b>	<b>(272,313)</b>	<b>1,489,354</b>
<b>Cost of Goods Sold</b>			
Subaward Expenses	124,975	-	124,975
<b>Total Cost of Goods Sold</b>	<b>124,975</b>	<b>-</b>	<b>124,975</b>
<b>Operating Expenses</b>			
<b>Employee Costs</b>			
Salaries and Wages	1,046,128	-	1,046,128
Vacation Expense	29,019	-	29,019
Payroll Taxes	86,005	-	86,005
Employee Benefits	49,390	-	49,390
401k Plan Contributions	81,287	-	81,287
Recruitment	234	-	234
Worker's Compensation Insurance	1,916	-	1,916
<b>Total Employee Costs</b>	<b>1,293,979</b>	<b>-</b>	<b>1,293,979</b>
Software Licenses & Services	58,691	-	58,691
<b>Meeting and Travel</b>			
Board-Related Expenses	2,863	-	2,863
Conference, Convention, Meeting	6,778	-	6,778
Meals and Entertainment	832	-	832
Travel	14,167	-	14,167
<b>Total Meeting and Travel</b>	<b>24,639</b>	<b>-</b>	<b>24,639</b>
Facilities and Equipment	77,306	-	77,306
Professional Fees	27,651	-	27,651
Credit Card Rebates	(1,700)	-	(1,700)

# Statement of Cash Flows

## Phoenix Bioinformatics Corporation For the year ended December 31, 2018

2018

---

### Cash Flows from Operating Activities

Receipts from customers	277,685
Payments to suppliers and employees	(1,523,431)
Cash receipts from other operating activities	1
<b>Total Cash Flows from Operating Activities</b>	<b>(1,245,744)</b>

### Cash Flows from Investing Activities

Payment for property, plant and equipment	(203,933)
Other cash items from investing activities	5,949
<b>Total Cash Flows from Investing Activities</b>	<b>(197,984)</b>

### Cash Flows from Financing Activities

Other cash items from financing activities	1,168,460
<b>Total Cash Flows from Financing Activities</b>	<b>1,168,460</b>

---

**Net Cash Flows** (275,269)

### Cash Balances

Cash and cash equivalents at beginning of period	942,773
Cash and cash equivalents at end of period	667,505
Net change in cash for period	(275,269)

	UNRESTRICTED	TEMPORARILY RESTRICTED	TOTAL
Insurance - Liability, D and O	1,538	-	1,538
Subscriptions and References	514	-	514
Office Supplies	1,523	-	1,523
License and Registration Fees	301	-	301
Transaction and Wire Fees	4,787	-	4,787
Interest Expense	436	-	436
Audit & Tax Preparation Fees	22,135	-	22,135
Depreciation Expense	177,765	-	177,765
<b>Total Operating Expenses</b>	<b>1,689,565</b>	<b>-</b>	<b>1,689,565</b>
<b>Operating Income</b>	<b>(52,873)</b>	<b>(272,313)</b>	<b>(325,185)</b>
<b>Other Income / (Expense)</b>			
Interest-Savings, Short-term CD	1	-	1
Unrealized Gain (Loss) on Investments	(3,016)	-	(3,016)
<b>Total Other Income / (Expense)</b>	<b>(3,014)</b>	<b>-</b>	<b>(3,014)</b>
<b>Increase (Decrease) in Net Assets</b>	<b>(55,887)</b>	<b>(272,313)</b>	<b>(328,200)</b>